Veracyte, a portfolio firm of two, Southern California venture capital investors--Domain Associates and Versant Ventures--has filed for an IPO, saying that it is looking to raised up to $74.7M in an IPO on the NASDAQ Global Market. Versant Ventures, based in Newport Beach, owns around 22% of Veracyte, with Domain Associates, which is in San Diego, owning around 19% of the molecular diagnostics tool maker. Veracyte is looking to list on the NASDAQ Global Market as VCYT. The IPO is being underwritten by Morgan Stanley, Leerink Swann, William Blair, and Cowen and Company. Veracyte's Chairman is Brian G. Atwood, Managing Director at Versant ventures; Versant also has a board seat overseen by Samuel D. Colella. Domain's investment is overseen by Jesse Treu. Veracyte is based in South San Francisco.
Top NewsMonday, September 23, 2013
Domain, Versant Portfolio Firm Plans IPO